peripheral nerve motor or sensory loss, Guillaine Barre type syndrome, multiple cranial nerve palsies Immune related adverse events (IrAE) occur in up to 90% patients administered ipilimumab up to 70% patients administered PD1/PDL1 inhibitors (pembrolizumab, nivolumab, atezolizumab) First line pembrolizumab (PD1) in lung cancer 1 in 10 had a G3 or G4 toxicity (better than chemotherapy) 1 in 20 stopped treatment due to toxicity These are very rarely immunosuppressive drugs sick patients are unlikely to have neutropenic sepsis mainstay of treatment of immune related adverse events - STEROIDS Immune Related Adverse Events: Primary care need to be aware that side effects may not be immediate: onset of these toxicities varies but usually starts within the first 8 to 12 weeks of initiation of treatment Reference: Brooks M, Olsson-Brown A

Furthermore, when we counted the number of live cells in si-P65 and si-EAAT3 cells exposed to RSL3 treatment, both cell lines exhibited a dose-dependent increase in cell death in EAAT3-silenced cells (Fig
On the one hand, reports such as those by the EAT-Lancet Commission asks consumers to embrace near plant-exclusive diets to reduce our impacts on planetary health (Willett et al., 2019)
The kidneys usually filter waste out of the blood, but when the kidneys are damaged, homocysteine can build up
CoQ10 is lipophilic and may necessitate formulation decisions to increase tissue concentrations